EGFR and lung cancer: There is an increasing interest in extending these panels to include genomic alterations associated with acquired resistance to target-based agents, which will become increasingly important as new drugs become available e.g. acquired mutations of EGFR such as p.(Thr790Met) and p.(Cys797Ser) [12] and multiple mutations of ALK such as p.(Phe1174Leu), p.(Leu1152Arg) and p.(Cys1156Tyr) in lung cancers [13] and acquired resistance EGFR p.(Ser492Arg) in colorectal cancer [14].